Company Overview and News
Aspire Mining Ltd (ASX:AKM) managing director David Paull speaks to Proactive Investors about the review of a rail feasibility study, carried out by wholly-owned rail subsidiary Northern Railways LLC, with the support of China Gezhouba International Ltd. This 547.7 kilometer railway extension will connect Aspire Mining’s large-scale Ovoot Coking Coal Project to the the town of Erdenet, and form part of the proposed Northern Rail Corridor extending across northern Mongolia into southern Russia.
Aspire Mining Ltd (ASX:AKM) has received results from pilot-scale carbonisation test work on a 300-kilogram bulk sample from its Nuurstei Coking Coal Project in Mongolia.
Aspire Mining Ltd (ASX:AKM) yesterday received a query from the ASX related to the company’s shares rising from 2.1 cents last Friday to 2.7 cents yesterday.
Aspire Mining Ltd (ASX:AKM) stands to gain from the growing support for the Erdenet to Ovoot Railway from both within Mongolia and the Tuva Republic in the Russian Federation.
Aspire Mining Ltd (ASX:AKM) managing director David Paull says "as a relatively small cap company, we've got our foot on a real giant, and realising the value in that giant is really what we're aiming to do through this year." The company’s plans for 2018 are focused on developing coking coal deposits in Mongolia to deliver international specification product to neighbouring international consumers.
Aspire Mining Ltd (ASX:AKM) has two key assets in Mongolia, the wholly-owned Ovoot Coking Coal Project and a 90% stake in the Nuurstei Coking Coal Project.
This fills a vacancy on the board of the Mongolian focused coal company caused by the recent retirement of long-serving non-executive chair David McSweeney.
Aspire Mining Ltd (ASX:AKM) is advancing a feasibility study for the Nuurstei Coking Coal Project in northern Mongolia with a bulk sample sent for coke oven testing.
Aspire Mining Ltd’s (ASX:AKM) rail subsidiary Northern Railways LLC has received a draft feasibility study which confirms the financial viability of the Erdenet to Ovoot Railway in Mongolia.
2018-06-22 - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
2018-06-22 - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
as of ET